Crinetics initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Crinetics (CRNX) with a Buy rating and no price target The firm says Crinetics is “revered” in the endocrine space with a pipeline that has the potential to generate tens of billions of sales. Paltusotine should be approved in September and become the standard of care for acromegaly and carcinoid syndrome, the analyst tells investors in a research note. TD also views the company’s early-stage pipeline as “impressive and robust.”